{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:40:16Z","timestamp":1761864016582},"reference-count":36,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,10,25]]},"DOI":"10.1253\/circj.cj-19-0494","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T22:03:28Z","timestamp":1567807408000},"page":"2242-2249","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Incidence and Details of Bleeding Events After Everolimus-Eluting Stent Implantation\u3000\u2015 7\u20138-Year Outcomes \u2015"],"prefix":"10.1253","volume":"83","author":[{"given":"Katsuya","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenobu","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Ohya","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidewo","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Fuku","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kurashiki Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, et al. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: Final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). <i>JACC Cardiovasc Interv<\/i> 2013; 6: 1263\u20131266.","DOI":"10.1016\/j.jcin.2013.07.009"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: Final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv<\/i> 2013; 6: 914\u2013922.","DOI":"10.1016\/j.jcin.2013.05.005"},{"key":"3","unstructured":"3. Mehran R, Giustino G, Baber U. DAPT duration after DES: What is the \u201cmandatory\u201d duration? <i>J Am Coll Cardiol<\/i> 2015; 65: 1103\u20131106."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yeh RW, Mauri L, Kereiakes DJ. Dual antiplatelet therapy duration following coronary stenting. <i>J Am Coll Cardiol<\/i> 2015; 65: 787\u2013790.","DOI":"10.1016\/j.jacc.2015.01.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. <i>J Am Coll Cardiol<\/i> 2015; 65: 2211\u20132221.","DOI":"10.1016\/j.jacc.2015.03.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sharma A, Agrawal S, Garg A, Vallakati A, Lavie CJ, Helft G. Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up. <i>Catheter Cardiovasc Interv<\/i> 2017; 90: 31\u201337.","DOI":"10.1002\/ccd.27123"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. <i>Eur Heart J<\/i> 2019; 40: 87\u2013165.","DOI":"10.1093\/eurheartj\/ehy394"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. <i>Circulation<\/i> 2007; 115: 2344\u20132351.","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. <i>N Engl J Med<\/i> 2001; 345: 494\u2013502.","DOI":"10.1056\/NEJMoa010746"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med<\/i> 2007; 357: 2001\u20132015.","DOI":"10.1056\/NEJMoa0706482"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: Meta-analysis of randomised controlled trials. <i>BMJ<\/i> 2015; 350: h1618.","DOI":"10.1136\/bmj.h1618"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Amin AP, Bachuwar A, Reid KJ, Chhatriwalla AK, Salisbury AC, Yeh RW, et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. <i>J Am Coll Cardiol<\/i> 2013; 61: 2130\u20132138.","DOI":"10.1016\/j.jacc.2013.02.044"},{"key":"13","unstructured":"13. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: Lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>Eur Heart J<\/i> 2017; 38: 804\u2013810."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Genereux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. <i>J Am Coll Cardiol<\/i> 2015; 66: 1036\u20131045.","DOI":"10.1016\/j.jacc.2015.06.1323"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. <i>Lancet<\/i> 2017; 389: 1025\u20131034.","DOI":"10.1016\/S0140-6736(17)30397-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS. <i>J Am Coll Cardiol<\/i> 2016; 67: 2224\u20132234.","DOI":"10.1016\/j.jacc.2016.02.064"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. <i>J Am Heart Assoc<\/i> 2018; 7: e008708.","DOI":"10.1161\/JAHA.118.008708"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. <i>J Am Coll Cardiol<\/i> 2016; 67: 2492\u20132502.","DOI":"10.1016\/j.jacc.2016.03.485"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. <i>JAMA<\/i> 2016; 315: 1735\u20131749.","DOI":"10.1001\/jama.2016.3775"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A risk score to predict bleeding in patients with acute coronary syndromes. <i>J Am Coll Cardiol<\/i> 2010; 55: 2556\u20132566.","DOI":"10.1016\/j.jacc.2009.09.076"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) bleeding score. <i>Circulation<\/i> 2009; 119: 1873\u20131882.","DOI":"10.1161\/CIRCULATIONAHA.108.828541"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. <i>N Engl J Med<\/i> 2010; 362: 1663\u20131674.","DOI":"10.1056\/NEJMoa0910496"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS, et al. Final 5-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: The COMPARE trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). <i>JACC Cardiovasc Interv<\/i> 2015; 8: 1157\u20131165.","DOI":"10.1016\/j.jcin.2015.03.028"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. <i>JAMA<\/i> 2013; 310: 2510\u20132522.","DOI":"10.1001\/jama.2013.282183"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). <i>J Am Coll Cardiol<\/i> 2012; 60: 1340\u20131348.","DOI":"10.1016\/j.jacc.2012.06.043"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shiomi H, Kozuma K, Morimoto T, Kadota K, Tanabe K, Morino Y, et al. 7-Year outcomes of a randomized trial comparing the first-generation sirolimus-eluting stent versus the new-generation everolimus-eluting stent: The RESET trial. <i>JACC Cardiovasc Interv<\/i> 2019; 12: 637\u2013647.","DOI":"10.1016\/j.jcin.2019.01.234"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Shiomi H, Kozuma K, Morimoto T, Igarashi K, Kadota K, Tanabe K, et al. Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: Final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial. <i>Circ Cardiovasc Interv<\/i> 2014; 7: 343\u2013354.","DOI":"10.1161\/CIRCINTERVENTIONS.113.001322"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, et al. Final 3-year outcome of a randomized trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: NOBORI Biolimus-eluting versus XIENCE\/PROMUS everolimus-eluting stent trial. <i>Circ Cardiovasc Interv<\/i> 2015; 8: e002817.","DOI":"10.1161\/CIRCINTERVENTIONS.115.002817"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. O\u2019Sullivan ED, Hughes J, Ferenbach DA. Renal aging: Causes and consequences. <i>J Am Soc Nephrol<\/i> 2017; 28: 407\u2013420.","DOI":"10.1681\/ASN.2015121308"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Stauder R, Valent P, Theurl I. Anemia at older age: Etiologies, clinical implications, and management. <i>Blood<\/i> 2018; 131: 505\u2013514.","DOI":"10.1182\/blood-2017-07-746446"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A. The epidemiological burden of atrial fibrillation: A challenge for clinicians and health care systems. <i>Eur Heart J<\/i> 2006; 27: 893\u2013894.","DOI":"10.1093\/eurheartj\/ehi651"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Galet C, Zhou Y, Eyck PT, Romanowski KS. Fall injuries, associated deaths, and 30-day readmission for subsequent falls are increasing in the elderly US population: A query of the WHO mortality database and National Readmission Database from 2010 to 2014. <i>Clin Epidemiol<\/i> 2018; 10: 1627\u20131637.","DOI":"10.2147\/CLEP.S181138"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Rao SV, McCoy LA, Spertus JA, Krone RJ, Singh M, Fitzgerald S, et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: A report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. <i>JACC Cardiovasc Interv<\/i> 2013; 6: 897\u2013904.","DOI":"10.1016\/j.jcin.2013.04.016"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. <i>N Engl J Med<\/i> 2019; 380: 1509\u20131524.","DOI":"10.1056\/NEJMoa1817083"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. <i>N Engl J Med<\/i> 2017; 377: 1513\u20131524.","DOI":"10.1056\/NEJMoa1708454"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. <i>N Engl J Med<\/i> 2016; 375: 2423\u20132434.","DOI":"10.1056\/NEJMoa1611594"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/11\/83_CJ-19-0494\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T03:21:40Z","timestamp":1572060100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/11\/83_CJ-19-0494\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-19-0494","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]}}}